These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38039782)

  • 21. Multiparametric MRI in men with clinical suspicion of prostate cancer undergoing repeat biopsy: a prospective comparison with clinical findings and histopathology.
    Boesen L; Nørgaard N; Løgager V; Balslev I; Thomsen HS
    Acta Radiol; 2018 Mar; 59(3):371-380. PubMed ID: 28679325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Who with suspected prostate cancer can benefit from Proclarix after multiparametric magnetic resonance imaging?
    Morote J; Campistol M; Regis L; Celma A; de Torres I; Semidey ME; Roche S; Mast R; Santamaria A; Planas J; Trilla E
    Int J Biol Markers; 2022 Jun; 37(2):218-223. PubMed ID: 35200058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Which men with non-malignant pathology at magnetic resonance imaging-targeted prostate biopsy and persistent PI-RADS 3-5 lesions should repeat biopsy?
    Castellani D; Pace G; Cecchini S; Franzese C; Cicconofri A; Romagnoli D; Del Rosso A; Possanzini M; Paci E; Dellabella M; Pierangeli T
    Urol Oncol; 2022 Oct; 40(10):452.e9-452.e16. PubMed ID: 35871992
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing the need for systematic biopsies in addition to targeted biopsies according to the characteristics of the index lesion at mpMRI. Results from a large, multi-institutional database.
    Barletta F; Mazzone E; Stabile A; Scuderi S; Brembilla G; de Angelis M; Cirulli GO; Cucchiara V; Gandaglia G; Karnes RJ; Roupret M; De Cobelli F; Montorsi F; Briganti A
    World J Urol; 2022 Nov; 40(11):2683-2688. PubMed ID: 36149448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of a second MRI and re-biopsy in patients with initial negative mpMRI-targeted and systematic biopsy for PIRADS ≥ 3 lesions.
    Zattoni F; Pereira LJP; Marra G; Valerio M; Olivier J; Puche-Sanz I; Rajwa P; Maggi M; Campi R; Amparore D; De Cillis S; Junlong Z; Guo H; La Bombarda G; Fuschi A; Veccia A; Ditonno F; Marquis A; Barletta F; Leni R; Serni S; Kasivisvanathan V; Antonelli A; Dal Moro F; Rivas JG; van den Bergh RCN; Briganti A; Gandaglia G; Novara G
    World J Urol; 2023 Nov; 41(11):3357-3366. PubMed ID: 37755520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of prostate MRI central review over the diagnostic performance of MRI-targeted biopsy: should we routinely ask for an expert second opinion?
    Stabile A; Sorce G; Barletta F; Brembilla G; Mazzone E; Pellegrino F; Cannoletta D; Cirulli GO; Gandaglia G; De Cobelli F; Montorsi F; Briganti A
    World J Urol; 2023 Nov; 41(11):3231-3237. PubMed ID: 36943477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of prostate cancer detection rate at targeted biopsy of hub and spoke centers mpMRI: experience matters.
    Droghetti M; Bianchi L; Gaudiano C; Corcioni B; Rustici A; Piazza P; Beretta C; Balestrazzi E; Costa F; Feruzzi A; Salvador M; Giunchi F; Fiorentino M; Golfieri R; Schiavina R; Brunocilla E
    Minerva Urol Nephrol; 2023 Feb; 75(1):42-49. PubMed ID: 35766364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Positive Predictive Value of Prostate Imaging Reporting and Data System Version 2 for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis.
    Mazzone E; Stabile A; Pellegrino F; Basile G; Cignoli D; Cirulli GO; Sorce G; Barletta F; Scuderi S; Bravi CA; Cucchiara V; Fossati N; Gandaglia G; Montorsi F; Briganti A
    Eur Urol Oncol; 2021 Oct; 4(5):697-713. PubMed ID: 33358543
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A 4K score/MRI-based nomogram for predicting prostate cancer, clinically significant prostate cancer, and unfavorable prostate cancer.
    Wagaskar VG; Sobotka S; Ratnani P; Young J; Lantz A; Parekh S; Falagario UG; Li L; Lewis S; Haines K; Punnen S; Wiklund P; Tewari A
    Cancer Rep (Hoboken); 2021 Aug; 4(4):e1357. PubMed ID: 33661541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate.
    Boschheidgen M; Schimmöller L; Doerfler S; Al-Monajjed R; Morawitz J; Ziayee F; Mally D; Quentin M; Arsov C; Albers P; Antoch G; Ullrich T
    Sci Rep; 2022 Apr; 12(1):6746. PubMed ID: 35469056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systematic versus Targeted Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy among Men with Visible Lesions.
    Patel HD; Koehne EL; Shea SM; Fang AM; Gorbonos A; Quek ML; Flanigan RC; Goldberg A; Rais-Bahrami S; Gupta GN
    J Urol; 2022 Jan; 207(1):108-117. PubMed ID: 34428091
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nomogram predicting prostate cancer in patients with negative prebiopsy multiparametric magnetic resonance.
    Chen M; Wang R; Zhang T; Zhang X; Wan Y; Fu X
    Future Oncol; 2022 Apr; 18(12):1473-1483. PubMed ID: 35105154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study.
    Emmett L; Buteau J; Papa N; Moon D; Thompson J; Roberts MJ; Rasiah K; Pattison DA; Yaxley J; Thomas P; Hutton AC; Agrawal S; Amin A; Blazevski A; Chalasani V; Ho B; Nguyen A; Liu V; Lee J; Sheehan-Dare G; Kooner R; Coughlin G; Chan L; Cusick T; Namdarian B; Kapoor J; Alghazo O; Woo HH; Lawrentschuk N; Murphy D; Hofman MS; Stricker P
    Eur Urol; 2021 Dec; 80(6):682-689. PubMed ID: 34465492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic Accuracy of Single-plane Biparametric and Multiparametric Magnetic Resonance Imaging in Prostate Cancer: A Randomized Noninferiority Trial in Biopsy-naïve Men.
    Russo F; Mazzetti S; Regge D; Ambrosini I; Giannini V; Manfredi M; De Luca S; Bollito E; Porpiglia F
    Eur Urol Oncol; 2021 Dec; 4(6):855-862. PubMed ID: 33893066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study.
    van der Leest M; Cornel E; Israël B; Hendriks R; Padhani AR; Hoogenboom M; Zamecnik P; Bakker D; Setiasti AY; Veltman J; van den Hout H; van der Lelij H; van Oort I; Klaver S; Debruyne F; Sedelaar M; Hannink G; Rovers M; Hulsbergen-van de Kaa C; Barentsz JO
    Eur Urol; 2019 Apr; 75(4):570-578. PubMed ID: 30477981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What's Next?
    Panebianco V; Barchetti G; Simone G; Del Monte M; Ciardi A; Grompone MD; Campa R; Indino EL; Barchetti F; Sciarra A; Leonardo C; Gallucci M; Catalano C
    Eur Urol; 2018 Jul; 74(1):48-54. PubMed ID: 29566957
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multi-institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI-RADS 3 lesions.
    Fang AM; Shumaker LA; Martin KD; Jackson JC; Fan RE; Khajir G; Patel HD; Soodana-Prakash N; Vourganti S; Filson CP; Sonn GA; Sprenkle PC; Gupta GN; Punnen S; Rais-Bahrami S
    Cancer; 2022 Sep; 128(18):3287-3296. PubMed ID: 35819253
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of a nomogram combining multiparametric magnetic resonance imaging and PSA-related parameters to enhance the detection of clinically significant cancer across different region.
    Zhou Z; Liang Z; Zuo Y; Zhou Y; Yan W; Wu X; Ji Z; Li H; Hu M; Ma L
    Prostate; 2022 Apr; 82(5):556-565. PubMed ID: 35098557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MRI-targeted or systematic random biopsies for prostate cancer diagnosis in biopsy naïve patients: follow-up of a PRECISION trial-like retrospective cohort.
    Luzzago S; de Cobelli O; Mistretta FA; Piccinelli ML; Lorusso V; Morelli M; Bianchi R; Catellani M; Cozzi G; Di Trapani E; Pricolo P; Alessi S; Ferro M; Marvaso G; Matei DV; Jereczek-Fossa BA; Petralia G; Musi G
    Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):406-413. PubMed ID: 32989259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective Evaluation of PI-RADS Version 2.1 for Prostate Cancer Detection and Investigation of Multiparametric MRI-derived Markers.
    Yilmaz EC; Shih JH; Belue MJ; Harmon SA; Phelps TE; Garcia C; Hazen LA; Toubaji A; Merino MJ; Gurram S; Choyke PL; Wood BJ; Pinto PA; Turkbey B
    Radiology; 2023 May; 307(4):e221309. PubMed ID: 37129493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.